NEW YORK, January 15, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including BlackBerry (NASDAQ: BBRY), BGC (NASDAQ: BGCP), CSX Corporation (NYSE: CSX), General Motors (NYSE: GM), and ZIOPHARM (NASDAQ: ZIOP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
BBRY Research Report: ( http://get.analystsreview.com/pdf/?c=BlackBerry&d=15-Jan-2015&s=BBRY ),
BGCP Research Report: ( http://get.analystsreview.com/pdf/?c=BGC&d=15-Jan-2015&s=BGCP ),
CSXResearch Report: ( http://get.analystsreview.com/pdf/?c=CSX%20Corporation&d=15-Jan-2015&s=CSX ),
GMResearch Report: ( http://get.analystsreview.com/pdf/?c=General%20Motors&d=15-Jan-2015&s=GM ),
ZIOPResearch Report: ( http://get.analystsreview.com/pdf/?c=ZIOPHARM&d=15-Jan-2015&s=ZIOP ).
Analyst Update: Business Outlook, Takeover Battle, Licensing Agreements, and Financial Results Reviewed by: Rohit Tuli, CFA®
The U.S. market sell-off showed no signs of easing on Wednesday, extending losses for fourth straight day as investors shunned risky assets and fled to safe havens amid deepening concerns over the global economic growth. The equity markets mirrored continued slump in commodities prices on Wednesday, led by the biggest plunge in Copper since 2011, after the World Bank cut its economic growth forecasts for this year and next. The Dow Jones Industrial Average ended the session 1.06% lower at 17,427.09, the S&P 500 lost 0.58% to close at 2,011.27, and the Nasdaq Composite dropped 0.48% to 4,639.32. Beaten-down commodity prices also weighed upon European markets on Wednesday. In Europe, energy and mining stocks led the decline following the prices of copper and oil. Meanwhile, Asian equities also ended lower as investors stayed on the sidelines amid deepening commodities rout and renewed concerns over world economic growth.
Shares of BlackBerry Ltd (BlackBerry) spiked in January 14, 2015 trading session, after rumors of Korean-Chaebol Samsung acquiring the former surfaced. The stock, however, fell in after-hours trading, after the companies denied any such talks. How much did Samsung offered to pay for each BlackBerry share? Read more on this in our research report.
BGC Partners Inc. (BGC) sweetened its offer for GFI Group Inc., as the takeover battle with CME Group intensifies. As per the latest news, the Company is offering $5.60 a share in a bid to thwart CME Group's plans to buy GFI. Prior to its revision, the tender offer price was for $5.45 per share. A further detailed analysis of this transaction and other recent purchases by BGC is available in our research report on BGC Partners.
CSX Corporation announced record Q4 FY 2014 net earnings of $491 million, an increase of 15.3% YoY. The Company also generated record fourth quarter EPS of $0.49, matching analysts' estimates, and up from $0.42 per share in Q4 FY 2013. Read more about the financial results and 2015 outlook in our research report on CSX Corporation.
Mary Barra of General Motors Company (General Motors) expects 2015 to be more profitable. The Company forecasted 2015 operating profit to increase from last year due mostly to growth in its two largest auto markets, China and the U.S. The Company also anticipates improved automotive results in all regions. Read more about the long-term outlook, management's viewpoint and the latest sales numbers in our research report on General Motors.
Shares of ZIOPHARM Oncology Inc. (ZIOPHARM) skyrocketed 54.5% in trade to end at $8.87, a day after the Company and Intrexon Corporation announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, for the development of non-viral adoptive cellular cancer immunotherapies. Read more about the terms of the agreement in our research report on ZIOPHARM.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review